AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9210003 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 21
Study 9210003 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 21
Study 9210003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 21
Study 7958571 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention programme (semistructured, using a flip‐over and a booklet) among pregnant women
Number of subjects: 624
Study 7958571 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention programme (semistructured, using a flip‐over and a booklet) among non-pregnant women
Number of subjects: 624
Study 7958571 — intervention group
Group type: COMPARATOR
Intervention: Control group for pregnant women
Number of subjects: 624
Study 7958571 — intervention group
Group type: COMPARATOR
Intervention: Control group for non-pregnant women
Number of subjects: 624
Study 3296236 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis (chymopapain injection)
Number of subjects: 156
Study 3296236 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 156
Study 29654122 — intervention group
Group type: EXPERIMENTAL
Intervention: Factual messages about chemicals in cigarette smoke and their health harms
Number of subjects: 719
Study 29654122 — intervention group
Group type: COMPARATOR
Intervention: Messages about not littering cigarette butts
Number of subjects: 719
Study 28395758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretherapeutic DPD deficiency screening (arm A)
Number of subjects: 1142
Study 28395758 — intervention group
Group type: COMPARATOR
Intervention: No pretherapy screening (arm B)
Number of subjects: 1142
Study 26306022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe in addition to statins
Number of subjects: 0
Study 26306022 — intervention group
Group type: COMPARATOR
Intervention: Statins alone
Number of subjects: 0
Study 24693625 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice (SnF2)
Number of subjects: 150
Study 24693625 — intervention group
Group type: COMPARATOR
Intervention: 0.3% triclosan/copolymer dentifrice (positive control)
Number of subjects: 150
Study 21165806 — intervention group
Group type: EXPERIMENTAL
Intervention: IHG1 (4×2‐min contractions at 30% MVC)
Number of subjects: 12
Study 21165806 — intervention group
Group type: EXPERIMENTAL
Intervention: IHG2 (8×1‐min contractions at 30% MVC)
Number of subjects: 12
Study 21165806 — intervention group
Group type: EXPERIMENTAL
Intervention: IHG3 (16×30‐s contractions at 30% MVC)
Number of subjects: 12
Study 21165806 — intervention group
Group type: COMPARATOR
Intervention: Sham (4×2‐min contractions at 3% MVC)
Number of subjects: 12
Study 21165806 — intervention group
Group type: EXPERIMENTAL
Intervention: IHG1
Number of subjects: 12
Study 21165806 — intervention group
Group type: EXPERIMENTAL
Intervention: IHG2
Number of subjects: 12
Study 21165806 — intervention group
Group type: EXPERIMENTAL
Intervention: IHG3
Number of subjects: 12
Study 18488808 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet formulation of sildenafil 100 mg
Number of subjects: 28
Study 17008146 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 254
Study 17008146 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 254
Study 17008146 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram and Naltrexone
Number of subjects: 254
Study 17008146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 12836151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (patients attending the pain center)
Number of subjects: 0
Study 12836151 — intervention group
Group type: EXPERIMENTAL
Intervention: Male participants
Number of subjects: 0
Study 12836151 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients younger than 65 years of age
Number of subjects: 0
Study 12836151 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients presenting with different types of chronic pain other than back pain
Number of subjects: 0
Study 12836151 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10847313 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg, controlled release)
Number of subjects: 19
Study 10847313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8794434 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 0
Study 8794434 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 0
Study 8794434 — intervention group
Group type: COMPARATOR
Intervention: Estrogen (previously incubated)
Number of subjects: 0
Study 1627433 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral LMF (chlorambucil, methotrexate, and fluorouracil) for 6 months followed by BCG skin scarifications monthly for up to 2 years
Number of subjects: 254
Study 1627433 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 254
Study 6328542 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketoconazole (200 mg twice daily for 5 days)
Number of subjects: 63
Study 6328542 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole 100 mg vaginal tablets (one per night for 6 days)
Number of subjects: 63
Study 31562909 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum partial length groESL sequence for species delineation
Number of subjects: 0
Study 31562909 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal partial sequences for intra-specific diversity analysis
Number of subjects: 0
Study 28318835 — intervention group
Group type: COMPARATOR
Intervention: d-serine (60mg/kg/d, 6 weeks)
Number of subjects: 16
Study 28318835 — intervention group
Group type: EXPERIMENTAL
Intervention: d-serine (open-label, 30-120mg/kg/d, n=21)
Number of subjects: 16
Study 28318835 — intervention group
Group type: COMPARATOR
Intervention: bitopertin (10mg, n=29)
Number of subjects: 16
Study 27372555 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet group (group T)
Number of subjects: 109
Study 27372555 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 109
Study 27372555 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 109
Study 23241791 — intervention group
Group type: EXPERIMENTAL
Intervention: Loupe magnification (×3.5)
Number of subjects: 81
Study 23241791 — intervention group
Group type: COMPARATOR
Intervention: Control (no loupe magnification)
Number of subjects: 81
Study 22819520 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration based on NOTT guidelines
Number of subjects: 31
Study 22819520 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking tests
Number of subjects: 31
Study 22819520 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant work-rate tests at 12 ml/min/kg
Number of subjects: 31
Study 22819520 — intervention group
Group type: EXPERIMENTAL
Intervention: Single exercise test at 40 W
Number of subjects: 31
Study 20465169 — intervention group
Group type: EXPERIMENTAL
Intervention: Coherent oscillation in the orthogonal direction of the main visual motion
Number of subjects: 0
Study 20465169 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation in phases or nonuniform amplitude
Number of subjects: 0
Study 20465169 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniform oscillation
Number of subjects: 0
Study 20465169 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual pattern perceived as more rigid
Number of subjects: 0
Study 17961726 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (autoSCT)
Number of subjects: 0
Study 17961726 — intervention group
Group type: COMPARATOR
Intervention: Continuation chemotherapy
Number of subjects: 0
Study 15564273 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt consumption and iodine content assessment
Number of subjects: 0
Study 15564273 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary iodine concentration measurement
Number of subjects: 0
Study 12147587 — intervention group
Group type: EXPERIMENTAL
Intervention: Grating acuity cards (Teller)
Number of subjects: 656
Study 12147587 — intervention group
Group type: COMPARATOR
Intervention: Recognition acuity charts (ETDRS or Lea symbol charts)
Number of subjects: 656
Study 10427139 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 gene mutations
Number of subjects: 178
Study 7483560 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational exposure to lead compounds
Number of subjects: 2723
Study 7483560 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to lead compounds)
Number of subjects: 2723
Study 2137995 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasole‐17‐propionate cream (topical corticosteroid) applied for 1 week prior to prick tests
Number of subjects: 0
Study 2137995 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (oral H1-antihistamine)
Number of subjects: 0
Study 2137995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (oral alpha 1-adrenoceptor agonist)
Number of subjects: 0
Study 2137995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7017685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive plasma exchange (IPE) combined with conventional anti-rejection therapy
Number of subjects: 60
Study 7017685 — intervention group
Group type: COMPARATOR
Intervention: Conventional anti-rejection therapy alone (control group)
Number of subjects: 60
Study 30712629 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable interference screw (BS) group
Number of subjects: 60
Study 30712629 — intervention group
Group type: COMPARATOR
Intervention: Cortical button (CB) group
Number of subjects: 60
Study 30712629 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 29856848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent use of NuvaRing® (three rings with a ring-free week in between rings)
Number of subjects: 120
Study 29856848 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous use of NuvaRing® (four rings without ring-free weeks)
Number of subjects: 120
Study 29856848 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intermittent and continuous use of NuvaRing®
Number of subjects: 120
Study 26501737 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (Genotropin®, Pfizer Inc.) at a dose of 0.035 mg/kg/day by subcutaneous injection for 24 months
Number of subjects: 0
Study 26501737 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study 25112521 — intervention group
Group type: EXPERIMENTAL
Intervention: Online 10 Hz, repetitive transcranial magnetic stimulation (rTMS) over the right precuneus
Number of subjects: 0
Study 25112521 — intervention group
Group type: COMPARATOR
Intervention: Vertex stimulation (control)
Number of subjects: 0
Study 25112521 — intervention group
Group type: EXPERIMENTAL
Intervention: rPPC stimulation (positive control)
Number of subjects: 0
Study 25112521 — intervention group
Group type: COMPARATOR
Intervention: No-TMS condition
Number of subjects: 0
Study 21815963 — intervention group
Group type: EXPERIMENTAL
Intervention: K/Mg solution pretreatment (n = 84)
Number of subjects: 170
Study 19054698 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment (high-dose and low-dose)
Number of subjects: 121
Study 19054698 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful thrombolysis
Number of subjects: 121
Study 17502505 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of amblyopia treatment (other than spectacle wear)
Number of subjects: 80
Study 15178163 — intervention group
Group type: EXPERIMENTAL
Intervention: Humorous film
Number of subjects: 35
Study 15178163 — intervention group
Group type: COMPARATOR
Intervention: Nonhumorous film
Number of subjects: 35
Study 12177657 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration, 4 IU subcutaneously every other day for 3 months
Number of subjects: 10
Study 10211615 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine needle cytology with suction
Number of subjects: 0
Study 10211615 — intervention group
Group type: COMPARATOR
Intervention: Fine needle cytology without suction
Number of subjects: 0
Study 7647026 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 0
Study 2112271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (150 mg twice daily)
Number of subjects: 0
Study 2112271 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (25 mg twice daily)
Number of subjects: 0
Study 2112271 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (25 mg twice daily) + Dipyridamole (150 mg twice daily)
Number of subjects: 0
Study 646077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine and thiopentone
Number of subjects: 0
Study 646077 — intervention group
Group type: COMPARATOR
Intervention: Ketamine alone
Number of subjects: 0
Study 31468650 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate infusion
Number of subjects: 16
Study 31468650 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 16
Study 26847152 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind Sound Resonance Technique (MSRT)
Number of subjects: 42
Study 26847152 — intervention group
Group type: COMPARATOR
Intervention: Supine Rest (SR)
Number of subjects: 42
Study 26318511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 9014
Study 26318511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study 23114462 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate (WPC) supplementation (40g/day)
Number of subjects: 80
Study 23114462 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control
Number of subjects: 80
Study 21091349 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX gel 2%
Number of subjects: 20
Study 21091349 — intervention group
Group type: COMPARATOR
Intervention: CHX gel after 3 minutes of 24% EDTA gel root surface etching
Number of subjects: 20
Study 18986598 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol-enriched margarine
Number of subjects: 47
Study 18986598 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol-enriched margarine
Number of subjects: 47
Study 18986598 — intervention group
Group type: COMPARATOR
Intervention: Margarine without added plant sterols or stanols
Number of subjects: 47
Study 16320175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed low-dosed magnetic field (100 uT, basic frequency 30 Hz with frequency modulation)
Number of subjects: 12
Study 16320175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed high-dosed magnetic field (8.4 mT, 10 Hz)
Number of subjects: 12
Study 16320175 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 12
Study 10556002 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPU (150 mg)
Number of subjects: 20
Study 10556002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8758049 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic electrical bioimpedance (TEB)
Number of subjects: 0
Study 8758049 — intervention group
Group type: COMPARATOR
Intervention: Oesophageal Doppler monitoring (ODM)
Number of subjects: 0
Study 1764957 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated naproxen 500 mg (2 tablets at night)
Number of subjects: 88
Study 1764957 — intervention group
Group type: COMPARATOR
Intervention: Normal release naproxen 500 mg (1 tablet twice daily)
Number of subjects: 88
Study 6637358 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg kg‐1 cimetidine orally
Number of subjects: 60
Study 6637358 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg kg‐1 cimetidine rectally
Number of subjects: 60
Study 6637358 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 60
Study 30633223 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) therapy for 8 weeks
Number of subjects: 86
Study 29408521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 120
Study 29408521 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 120
Study 26735531 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot pump (A-V Impulse System)
Number of subjects: 120
Study 26735531 — intervention group
Group type: COMPARATOR
Intervention: No foot pump
Number of subjects: 120
Study 24158736 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 110
Study 24158736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 21989603 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 30
Study 21989603 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 30
Study 21989603 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 30
Study 20630899 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus S-1 combination therapy
Number of subjects: 100
Study 20630899 — intervention group
Group type: COMPARATOR
Intervention: S-1 monotherapy
Number of subjects: 100
Study 17205320 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine patch (14 mg)
Number of subjects: 30
Study 17205320 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 30
Study 17205320 — intervention group
Group type: EXPERIMENTAL
Intervention: Low abstinence reinforcement condition ($5.00 available)
Number of subjects: 30
Study 17205320 — intervention group
Group type: EXPERIMENTAL
Intervention: High abstinence reinforcement condition ($20.00 available)
Number of subjects: 30
Study 17205320 — intervention group
Group type: COMPARATOR
Intervention: Control session (monetary consequences every 30 s regardless of smoking)
Number of subjects: 30
Study 16343112 — intervention group
Group type: EXPERIMENTAL
Intervention: Er : YAG laser at 16 Hz and 200 mJ input (120 mJ output)
Number of subjects: 90
Study 16343112 — intervention group
Group type: EXPERIMENTAL
Intervention: Er : YAG laser at 16 Hz and 400 mJ input (240 mJ output)
Number of subjects: 90
Study 16343112 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd : YAG laser at 15 Hz and 1 W input (0.4 W output)
Number of subjects: 90
Study 16343112 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd : YAG laser at 15 Hz and 2 W input (0.8 W output)
Number of subjects: 90
Study 16343112 — intervention group
Group type: COMPARATOR
Intervention: 17% EDTAC
Number of subjects: 90
Study 12505116 — intervention group
Group type: EXPERIMENTAL
Intervention: House officer-attending physician conference room discussion plus attending physician-patient interaction
Number of subjects: 393
Study 12505116 — intervention group
Group type: COMPARATOR
Intervention: Exclusive house officer-attending physician conference room discussion
Number of subjects: 393
Study 12505116 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive house officer-attending physician discussion in the examining room with the patient present
Number of subjects: 393
Study 9649660 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymecycline (300 mg/day for 2 weeks, then 150 mg/day for 10 weeks)
Number of subjects: 144
Study 9649660 — intervention group
Group type: COMPARATOR
Intervention: Minocycline (100 mg/day for 2 weeks then 100 mg every other day for 10 weeks)
Number of subjects: 144
Study 9649660 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymecycline
Number of subjects: 144
Study 9649660 — intervention group
Group type: COMPARATOR
Intervention: Minocycline
Number of subjects: 144
Study 7545768 — intervention group
Group type: EXPERIMENTAL
Intervention: Device implantation
Number of subjects: 0
Study 7545768 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy
Number of subjects: 0
Study 7545768 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic studies
Number of subjects: 0
Study 7545768 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 0
Study 30208761 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn 2 Learn intervention (high-intensity interval training), 3 sessions per week for 14 weeks.
Number of subjects: 68
Study 30208761 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention).
Number of subjects: 68
Study 30208761 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn 2 Learn intervention (high-intensity interval training).
Number of subjects: 68
Study 28622405 — intervention group
Group type: EXPERIMENTAL
Intervention: Arte con Salud intervention
Number of subjects: 86
Study 28622405 — intervention group
Group type: COMPARATOR
Intervention: Community-academic collaboration
Number of subjects: 86
Study 22535548 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Visits (GV)
Number of subjects: 1024
Study 22535548 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 1024
Study 24063843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 407
Study 24063843 — intervention group
Group type: COMPARATOR
Intervention: No abciximab
Number of subjects: 407
Study 24063843 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual aspiration
Number of subjects: 407
Study 24063843 — intervention group
Group type: COMPARATOR
Intervention: No aspiration
Number of subjects: 407
Study 21616977 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (75 mg)
Number of subjects: 14
Study 21616977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19144729 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined testosterone (40 mg daily for women, 80 mg twice daily for men) and nutritional supplement (475 kcal/d)
Number of subjects: 49
Study 19144729 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined testosterone and nutritional supplement
Number of subjects: 49
Study 19144729 — intervention group
Group type: COMPARATOR
Intervention: Testosterone treatment
Number of subjects: 49
Study 19144729 — intervention group
Group type: COMPARATOR
Intervention: Nutritional supplement
Number of subjects: 49
Study 19144729 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 49
Study 17545208 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based system for assessing tremor using a shape-tracing task on a graphic tablet.
Number of subjects: 22